Hotsia.Com : เที่ยวสะใจ

The Chronic Kidney Disease Solution™ By Shelly Manning It is an eBook that includes the most popular methods to care and manage kidney diseases by following the information provided in it. This easily readable eBook covers up various important topics like what is chronic kidney disease, how it is caused, how it can be diagnosed, tissue damages caused by chronic inflammation, how your condition is affected by gut biome, choices for powerful lifestyle and chronic kidney disease with natural tools etc.

---

Bone and mineral disorders in CKD

Bone and mineral disorders, commonly referred to as Chronic Kidney Disease-Mineral and Bone Disorder (CKD-MBD), are common complications of chronic kidney disease (CKD). These disorders result from dysregulation of calcium, phosphorus, parathyroid hormone (PTH), and vitamin D metabolism, which leads to abnormalities in bone health, vascular calcification, and cardiovascular disease. The complex interplay between the kidneys, bones, parathyroid glands, and the gastrointestinal system underlies the development of CKD-MBD, and these imbalances can occur as early as stage 2 CKD, worsening with disease progression.

Pathophysiology of CKD-MBD

1. Phosphate Retention: As kidney function declines, phosphate excretion decreases, leading to phosphate retention. Phosphate is normally filtered by the kidneys, but in CKD, reduced glomerular filtration rate (GFR) leads to increased serum phosphate levels. Hyperphosphatemia triggers a cascade of metabolic changes, including the suppression of calcitriol (active vitamin D) and the stimulation of parathyroid hormone (PTH) production, both of which exacerbate bone and mineral disorders.
2. Decreased Calcitriol Production: The kidneys convert 25-hydroxyvitamin D into its active form, 1,25-dihydroxyvitamin D (calcitriol). In CKD, the capacity of the kidneys to produce calcitriol decreases as kidney function deteriorates. This reduction leads to impaired intestinal calcium absorption, causing hypocalcemia and stimulating PTH secretion. Decreased calcitriol also contributes to reduced bone mineralization and worsens the imbalance in calcium and phosphate metabolism.
3. Secondary Hyperparathyroidism: The persistent elevation of phosphate levels, coupled with hypocalcemia and reduced calcitriol, stimulates the parathyroid glands to produce more PTH, a condition known as secondary hyperparathyroidism. PTH acts to normalize calcium and phosphate levels by increasing calcium reabsorption in the kidneys, stimulating calcium release from bones, and enhancing phosphate excretion. However, in CKD, this compensatory mechanism becomes maladaptive. High PTH levels cause excessive bone turnover, leading to bone weakening and remodeling abnormalities.
4. Bone Turnover Disorders: CKD patients can experience various types of bone disorders, depending on the balance between bone formation and resorption:
   • High Bone Turnover Disease (Osteitis Fibrosa): This is caused by elevated PTH levels and is characterized by increased bone resorption and formation. It leads to bone pain, fractures, and deformities.
   • Adynamic Bone Disease: In this condition, there is low bone turnover due to over-suppression of PTH, often as a result of aggressive phosphate binder or vitamin D analog use. This leads to fragile bones that are more prone to fractures.
   • Mixed Uremic Osteodystrophy: This is a combination of high and low bone turnover, where both osteitis fibrosa and adynamic bone disease coexist.
5. Vascular Calcification: Vascular calcification is a hallmark of CKD-MBD and is a major contributor to cardiovascular mortality in CKD patients. Hyperphosphatemia and elevated calcium-phosphate product promote calcium deposition in the blood vessel walls. In CKD, the process of vascular calcification is similar to bone formation, where vascular smooth muscle cells undergo osteogenic transformation, resulting in arterial stiffness and calcification. This increases the risk of cardiovascular events such as myocardial infarction, stroke, and heart failure.
6. Fibroblast Growth Factor 23 (FGF23): FGF23 is a hormone produced by osteocytes that regulates phosphate homeostasis by promoting renal phosphate excretion and suppressing calcitriol production. In early CKD, FGF23 levels rise in response to phosphate retention. However, as CKD progresses, elevated FGF23 can no longer compensate for declining kidney function, leading to persistent hyperphosphatemia and contributing to secondary hyperparathyroidism. High FGF23 levels are also associated with left ventricular hypertrophy and increased cardiovascular mortality in CKD patients.

Clinical Manifestations of CKD-MBD

1. Bone Pain and Fractures: CKD-MBD often leads to skeletal abnormalities that cause bone pain, particularly in the lower back, hips, and legs. The weakening of bones increases the risk of fractures, especially in the hips and spine. These fractures are associated with high morbidity and mortality, particularly in patients on dialysis.
2. Muscle Weakness: Phosphate imbalances and vitamin D deficiency can contribute to muscle weakness and fatigue. CKD patients may experience difficulty walking, climbing stairs, or performing daily activities due to reduced muscle function.
3. Growth Retardation in Children: Children with CKD-MBD may experience impaired growth due to bone abnormalities and disturbances in calcium and phosphate metabolism. The delayed bone growth can lead to short stature and developmental issues if not treated.
4. Vascular Calcification and Cardiovascular Disease: Vascular calcification contributes to arterial stiffness, hypertension, and left ventricular hypertrophy, all of which increase the risk of cardiovascular disease. CKD patients with vascular calcification are at higher risk for heart failure, ischemic heart disease, and sudden cardiac death.
5. Itching (Pruritus): Severe itching is a common symptom in CKD-MBD and is thought to be related to hyperphosphatemia, high PTH levels, and uremic toxins. Itching can significantly reduce quality of life, especially in dialysis patients.

Diagnosis of CKD-MBD

Diagnosis of CKD-MBD involves a combination of clinical assessment, laboratory measurements, and imaging techniques to evaluate bone health, mineral metabolism, and the extent of vascular calcification:

1. Serum Biomarkers:
   • Calcium and Phosphate: Serum calcium and phosphate levels are measured to assess mineral balance. Hyperphosphatemia and hypocalcemia are common in CKD-MBD.
   • PTH: Intact PTH levels are used to evaluate parathyroid gland activity and to assess bone turnover status.
   • Vitamin D: Levels of 25-hydroxyvitamin D and 1,25-dihydroxyvitamin D are measured to assess vitamin D deficiency and calcitriol production.
   • FGF23: Elevated FGF23 levels indicate phosphate retention and contribute to secondary hyperparathyroidism.
2. Bone Density Testing: Dual-energy X-ray absorptiometry (DEXA) scans are used to measure bone mineral density and assess fracture risk in CKD patients.
3. Bone Biopsy: A bone biopsy may be performed to definitively diagnose the type of bone disorder present in CKD patients, though it is not commonly done in clinical practice.
4. Imaging for Vascular Calcification: X-rays, CT scans, or ultrasound may be used to detect vascular calcification in CKD patients. Calcification in the coronary arteries, aorta, and peripheral vessels can indicate an increased risk of cardiovascular events.

Treatment of CKD-MBD

Management of CKD-MBD focuses on controlling phosphate levels, correcting calcium and vitamin D imbalances, and managing PTH levels to prevent bone disease and vascular calcification.

1. Phosphate Control:
   • Dietary Phosphate Restriction: CKD patients are advised to reduce dietary phosphate intake by limiting high-phosphate foods such as dairy products, processed meats, and soft drinks.
   • Phosphate Binders: Oral phosphate binders are used to reduce phosphate absorption from the gastrointestinal tract. Calcium-based binders (e.g., calcium carbonate) and non-calcium-based binders (e.g., sevelamer, lanthanum) are commonly used.
2. Vitamin D Supplementation:
   • Active Vitamin D Analogs: Calcitriol or its analogs (e.g., paricalcitol) are used to correct vitamin D deficiency and reduce PTH levels. These agents improve calcium absorption and help control secondary hyperparathyroidism.
   • Nutritional Vitamin D (Cholecalciferol or Ergocalciferol): In early CKD, nutritional vitamin D supplementation may be used to correct deficiency and prevent the progression of CKD-MBD.
3. Management of Secondary Hyperparathyroidism:
   • Calcimimetics: Calcimimetic agents (e.g., cinacalcet) mimic calcium and bind to the calcium-sensing receptor on the parathyroid glands, reducing PTH secretion. These drugs are particularly useful in patients with severe hyperparathyroidism who do not respond to vitamin D therapy.
   • Parathyroidectomy: In cases of refractory secondary hyperparathyroidism, where medical management fails, surgical removal of part of the parathyroid glands (parathyroidectomy) may be necessary to reduce PTH levels and prevent further bone damage.
4. Treatment of Vascular Calcification:
   • Controlling phosphate levels and avoiding calcium overload are key to preventing vascular calcification. Use of non-calcium phosphate binders and controlling PTH levels can help minimize calcification risks.

Emerging Therapies

1. FGF23 Inhibitors: Therapies targeting FGF23 are being explored as a way to modulate phosphate homeostasis and prevent vascular calcification in CKD patients.
2. New Vitamin D Analogs and Calcimimetics: Novel vitamin D analogs and calcimimetics with improved safety profiles and fewer side effects are being developed to optimize the treatment of CKD-MBD.

Conclusion

CKD-MBD is a multifaceted disorder involving dysregulated mineral metabolism, bone disease, and vascular calcification. It significantly increases the risk of fractures, cardiovascular disease, and mortality in CKD patients. Early identification and comprehensive management of CKD-MBD through phosphate control, vitamin D supplementation, and PTH regulation are essential to improving outcomes and preventing complications. Effective treatment requires a multidisciplinary approach, involving nephrologists, dietitians, and other healthcare providers to ensure optimal care for CKD patients at risk of bone and mineral disorders.

The Chronic Kidney Disease Solution™ By Shelly Manning It is an eBook that includes the most popular methods to care and manage kidney diseases by following the information provided in it. This easily readable eBook covers up various important topics like what is chronic kidney disease, how it is caused, how it can be diagnosed, tissue damages caused by chronic inflammation, how your condition is affected by gut biome, choices for powerful lifestyle and chronic kidney disease with natural tools etc.

I’m Mr.Hotsia, sharing 30 years of travel experiences with readers worldwide. This review is based on my personal journey and what I’ve learned along the way. I share my experiences on www.hotsia.com